Skip to content

Top 5 stories on co-infections and co-morbidities in people with HIV from IAS 2023

sqofield/Shutterstock.com

Top 5 HIV treatment stories from IAS 2023

Rhiannon Neale Photography

Integrase inhibitors more likely to be linked to depression and suicidality than other HIV drugs

Tero Vesalainen/Shutterstock.com

Top 5 stories on HIV in Africa from IAS 2023

Shutterstock Studios HIV in View gallery

Resistance history does not affect response to dolutegravir / lamivudine

Gary Blick at IAS 2023. Photo by Roger Pebody.

Immediate ART associated with fewer deaths in Thailand, but starting a week or two later may lead to less virological failure

Sirinya Teeraananchai at IAS 2023.

Injectable HIV treatment unlikely to be arriving soon in the global south

Dr Carolyn Bolton Moore at IAS 2023.

Adherence counselling reverses viral rebound on dolutegravir in 95% of cases

Dr Andrew Hill at IAS 2023. Photo by Roger Pebody.

Integrase inhibitors raise the risk of diabetes regardless of weight gain

Dhanushi Rupasinghe at IAS 2023.